Key Themes Explored in 2019
Ensure credibility:
Bring new levels of data quality with replicable study standards, transparency, technological assurance and analytical excellence
Expand your horizons:
Witness the emerging uses of RWE in drug development and the increasingly usable range of data sources offering new level of quality insights
Unite and grow capabilities:
Accelerate the growth of the data ecosystem through collaboration with more stakeholders, breaking silos and maximising combined expertise
The event will be driven by pharma senior executives, key stakeholders and technology experts across the industry:
鈥� David Leather, VP, Medical Respiratory Franchise, Salford Lung Study Lead, GSK
鈥� Khair ElZarrad, Deputy Director, Office of Medical Policy, FDA
鈥� Christoph von der Goltz, Senior Director, Head of HEOR and RWE, Lundbeck
鈥� Giuseppe Rosano, Member CVWP, European Medicines Agency, Consultant Cardiologist, Agenzia Italiana del Farmaco
鈥� Andrew Bate, Senior Director, Analytics Team Lead, Epidemiology, Pfizer
鈥� Amanda Golembesky, Executive Director, Epidemiology, Boehringer Ingelheim
